Xilio Therapeutics, Inc.

NasdaqCM:XLO Stock Report

Market Cap: US$50.6m

Xilio Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Rene Russo

Chief executive officer

US$6.5m

Total compensation

CEO salary percentage9.98%
CEO tenure7yrs
CEO ownership0.4%
Management average tenure2.9yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

Analysis Article • Feb 13

We're Hopeful That Xilio Therapeutics (NASDAQ:XLO) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, Xilio Therapeutics...
Analysis Article • Oct 25

Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jul 12

Here's Why We're A Bit Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Aug 11

We Think Xilio Therapeutics (NASDAQ:XLO) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

CEO Compensation Analysis

How has Rene Russo's remuneration changed compared to Xilio Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$31m

Dec 31 2025US$6mUS$644k

-US$35m

Sep 30 2025n/an/a

-US$58m

Jun 30 2025n/an/a

-US$56m

Mar 31 2025n/an/a

-US$54m

Dec 31 2024US$1mUS$614k

-US$58m

Sep 30 2024n/an/a

-US$63m

Jun 30 2024n/an/a

-US$66m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$3mUS$598k

-US$76m

Sep 30 2023n/an/a

-US$81m

Jun 30 2023n/an/a

-US$84m

Mar 31 2023n/an/a

-US$90m

Dec 31 2022US$2mUS$575k

-US$88m

Sep 30 2022n/an/a

-US$85m

Jun 30 2022n/an/a

-US$82m

Mar 31 2022n/an/a

-US$80m

Dec 31 2021US$5mUS$485k

-US$76m

Sep 30 2021n/an/a

-US$77m

Jun 30 2021n/an/a

-US$75m

Mar 31 2021n/an/a

-US$64m

Dec 31 2020US$3mUS$450k

-US$55m

Compensation vs Market: Rene's total compensation ($USD6.45M) is above average for companies of similar size in the US market ($USD629.02K).

Compensation vs Earnings: Rene's compensation has increased whilst the company is unprofitable.

CEO

Rene Russo (50 yo)

7yrs
Tenure
US$6,451,495
Compensation

Dr. Rene Russo, BCPS, PharmD., is Scientific Advisor of Pylum Biosciences, Inc. Dr. Russo serves as Director at Celsius Therapeutics, Inc. since May 2020. Since May 2019, Dr. Russo has been the Chief Execu...

Leadership Team

NamePositionTenureCompensationOwnership
Rene Russo
President7yrsUS$6.45m0.39%
$ 196.6k
Christopher Frankenfield
CFO & COO2.8yrsUS$3.23m0.030%
$ 15.0k
Katarina Luptakova
Chief Medical Officer2.7yrsUS$2.20m0.040%
$ 20.1k
Kevin Brennan
Senior Vice President of Finance & Accounting3.1yrsno data0.0076%
$ 3.9k
Uli Bialucha
Chief Scientific Officer3.8yrsno datano data
Nathan McBride
Chief Information Officer3.7yrsno datano data
Caroline Hensley
Chief Legal Officer1.4yrsno datano data
Scott Coleman
Chief Development Officer2.7yrsno datano data
Ruth Moulin
Senior Vice President of Medical Affairsno datano datano data
2.9yrs
Average Tenure
49.5yo
Average Age

Experienced Management: XLO's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rene Russo
President7yrsUS$6.45m0.39%
$ 196.6k
Cheryl Blanchard
Independent Directorless than a yearno datano data
James Shannon
Independent Director1.9yrsUS$62.45k0.17%
$ 84.6k
Daniel Curran
Independent Director5.4yrsUS$63.62k0%
$ 0
Aoife Brennan
Independent Director1.9yrsUS$63.12k0%
$ 0
Sara Bonstein
Independent Chairman4.8yrsUS$70.32k0%
$ 0
Robert Ross
Independent Director3.9yrsUS$60.74k0%
$ 0
Yuan Xu
Independent Director4.3yrsUS$59.62k0%
$ 0
Akintunde Bello
Independent Directorless than a yearUS$46.29kno data
3.9yrs
Average Tenure
57yo
Average Age

Experienced Board: XLO's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/31 12:15
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xilio Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daina GrayboschLeerink Partners LLC